Levels of soluble tumor necrosis factor receptor 1 and 2 are associated with survival after ST segment elevation myocardial infarction

Figures

• 

  Figure 1. The design of the study.

• 

  Figure 2. Plasma levels of (a) sTNFR1 (b) sTNFR2 in blood samples obtained from STEMI patients before, 1–3 days after PCI and 3 months after PCI as compared to healthy donors. Statistical analyses were conducted using Kruskal Wallis test followed by Dunn´s multiple comparison test, the whiskers show the 10–90th percentile with all outliers. (NS = not significant, **** = p < 0.0001).

• 

  Figure 3. Plasma levels of (a) sTNFR1 and (b) sTNFR2 in paired samples obtained at different time points during STEMI. Statistical analyses were conducted using the Friedman test followed by Dunn´s multiple comparison test, and data are shown as median and 10–90th percentile with all outliers. ((NS = not significant, * = p < 0.05, ** = p < 0.01).

• 

  Figure 4. Correlation matrix showing Spearman r values for correlations between levels of sTNFR1 and sTNFR2 at the different timepoints.

• 

  Figure 5. Kaplan–Meier curves comparing survival for patients with levels above and below the median value for (a, c, e) sTNFR1 (b, d, f) sTNFR2. Curves in (a) and (b) are for acute samples, while (c) and (d) are for samples collected 1–3 days after PCI and (e) and (f) are for samples collected 3 months after PCI. Survival analysis was performed using the log-rank test (Mantel-Cox method).

• 

  Figure 6. Kaplan–Meier curves comparing survival for patients with levels above and within the reference range for the 40 healthy donors for sTNFR2 in (a) acute samples and (b) samples collected 1–3 days after PCI and (c) samples collected 3 months after PCI. Survival analysis was performed using the log-rank test (Mantel-Cox method).